Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Secarna Pharmaceuticals, Scenic Biotech Enter Drug Discovery & Co-Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Secarna Pharmaceuticals, Scenic Biotech Enter Drug Discovery & Co-Development Pact

Will jointly develop a first-in-class disease-modifying oligonucleotide against a newly validated target relevant for rare genetic disorders as well as broader disease conditions.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Secarna Pharmaceuticals, a biopharmaceutical company, has signed an agreement with Scenic Biotech B.V., a pioneer in modifier therapies for severe genetic diseases, covering the discovery and co-development of oligonucleotides against a novel target identified and validated by Scenic Biotech’s proprietary Cell-Seq platform.

Secarna will lead the oligonucleotide discovery part of the collaboration, bringing OligoCreator, its proprietary AI-empowered oligonucleotide discovery and development platform, to the co-development. OligoCreator has been shown to greatly expedite the drug discovery process, from target selection to therapeutic development, identifying and characterizing potentially safe and efficacious therapeutic candidates faster. Within the collaboration, Secarna will utilize its platform to identify promising candidates, while Scenic will add its expertise on target and disease biology. 

“We are really excited to collaborate with Scenic to develop first-in-class disease-modifying oligonucleotide therapies for severe genetic diseases. We were drawn together because both companies are working to tackle challenging-to-treat diseases in new ways, and we saw much synergy between our technologies and experience,” said Konstantin Petropoulos, PhD, CEO of Secarna Pharmaceuticals. “From selecting the best target with the input of Scenic’s Cell-Seq platform to discovering the best oligonucleotide therapeutic candidates with Secarna’s OligoCreator technology, we look forward to breaking new ground to jointly develop novel treatment options for patients in need.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics